Tumor Necrosis Factor Receptor 1 (TNFR1, also known as TNFRSF1A) is a member of the tumor necrosis factor receptor superfamily that transduces the pro-inflammatory and pro-apoptotic effects of tumor necrosis factor-alpha (TNF-α). TNFR1 is a master regulator of inflammation, cell survival, and cell death pathways. In the central nervous system, TNFR1 signaling contributes to neuroinflammation, excitotoxicity, and neuronal loss in Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), stroke, and traumatic brain injury. Understanding TNFR1's dual roles in both protective immunity and pathological neurodegeneration is crucial for developing targeted therapeutics.
[^1]
[^2]
Gene: [TNFRSF1A](/genes/tnfrsf1a)
[^3]
UniProt ID: [P19438](https://www.uniprot.org/uniprot/P19438)
[^4]
PDB Structure: 1TNR, 1FVC, 2AZ5, 5US7
[^5]
Molecular Weight: ~55 kDa (type I transmembrane protein)
[^6]
Subcellular Localization: Plasma membrane, endosomes, Golgi apparatus
[^7]
Protein Family: TNF receptor superfamily, TNFR1 subfamily
[^8]
[^9]
TNFR1 is a type I transmembrane receptor with characteristic features:
- Extracellular domain (ECD): Contains four cysteine-rich domains (CRDs) that bind TNF-α
- Transmembrane domain: Single α-helical transmembrane segment
- Cytoplasmic domain (DD): Contains the death domain (~70 aa) for signaling
- Pre-ligand assembly: TNFR1 forms pre-assembled trimers in the membrane
- Soluble receptor: Can be shed as a soluble receptor (sTNFR1) that neutralizes TNF-α
Crystal structures of TNFR1 (PDB: 1TNR, 1FVC) show the trimeric receptor-ligand complex.
TNFR1 signaling has complex physiological roles:
- Pro-inflammatory signaling: Activates NF-κB and MAPK pathways via TRADD/TRAF2
- Apoptosis induction: Can trigger apoptosis through FADD/caspase-8 pathway
- Necroptosis: Partners with RIPK3 for necroptotic cell death under certain conditions
- Immune regulation: Essential for mounting inflammatory responses to infection
- Cell survival: NF-κB activation promotes cell survival and proliferation
TNFR1 is upregulated in AD brains and contributes to pathogenesis:
- Neuroinflammation: TNF-α/TNFR1 signaling drives chronic neuroinflammation in AD
- Synaptic dysfunction: TNFR1 activation impairs synaptic plasticity and memory
- Amyloid-β synergy: Aβ and TNF-α synergistically promote neuronal death
- Glial activation: TNFR1 on microglia and astrocytes promotes pro-inflammatory phenotype
- Therapeutic targeting: TNF-α inhibitors (etanercept, infliximab) have shown promise in AD models
TNFR1 contributes to dopaminergic neuron loss:
- Mitochondrial dysfunction: TNF-α signaling through TNFR1 impairs mitochondrial function
- Microglial activation: TNFR1 mediates microglial activation and neurotoxic cytokine release
- Alpha-synuclein: TNF-α potentiates α-synuclein toxicity
- Neuroprotection: TNFR1 deficiency protects against MPTP-induced PD
TNFR1 plays a role in motor neuron degeneration:
- Astrocyte activation: TNFR1 on astrocytes promotes inflammatory responses
- Microglial toxicity: TNFR1-mediated inflammation contributes to non-cell autonomous damage
- Disease progression: TNFR1 levels correlate with disease severity
¶ Stroke and Traumatic Brain Injury
TNFR1 mediates secondary neuronal damage:
- Ischemic injury: TNF-α/TNFR1 signaling exacerbates ischemic brain damage
- Excitotoxicity: TNFR1 synergizes with glutamate toxicity
- Blood-brain barrier disruption: TNFR1 contributes to BBB breakdown
TNFR1 is a major drug target for neuroinflammatory disorders:
- TNF-α inhibitors: Etanercept (Enbrel), Infliximab (Remicade), Adalimumab (Humira)
- TNFR1 antagonists: Soluble receptors and blocking antibodies
- Signaling inhibitors: NF-κB and MAPK pathway inhibitors
- Challenges: Systemic TNF inhibition causes immunosuppression
- Brain-penetrant drugs: Newer approaches aim to target CNS TNFR1 selectively